Carson Lisa Cabott reported grant involving 108,000 shares of Phio Pharmaceuticals Corp. at $0.00 for $0 on Sep 28, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Financial Officer
Chief Financial Officer
Filed Sep 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
108,000Common Stock, $.0001 par value
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
189,112Direct
Trade date
Sep 28, 2026Grant
Filed
Sep 29, 2026, 4:01 PM ET1-day reporting delay
Accession
0001683168-26-007481Code A · Transaction 230891
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

PHIO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PHIO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +8.7%1w ago −1.9%1d ago −1.9%
Returns since7d −3.9%30d −12%90d180d1y

Footnotes in full

F1: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2: Includes shares of common stock underlying unvested restricted stock units.